{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:38:03Z","timestamp":1784907483427,"version":"3.55.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Antiphospholipid syndrome (APS) is a multisystemic autoimmune disorder characterized by thrombotic events and\/or gestational morbidity in patients with antiphospholipid antibodies (aPL). In a previous single center study, APS-related clinical manifestations that were not included in the classification criteria (livedo reticularis, thrombocytopenia, leukopenia) were associated with the presence of circulating immune-complexes (CIC) formed by beta-2-glycoprotein-I (B2GP1) and anti-B2GP1 antibodies (B2-CIC). We have performed a multicenter study on APS features associated with the presence of B2-CIC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, cross-sectional and observational study was conducted on 303 patients recruited from six European hospitals who fulfilled APS classification criteria: 165 patients had primary APS and 138 APS associated with other systemic autoimmune diseases (mainly systemic lupus erythematosus, N=112). Prevalence of B2-CIC (IgG\/IgM isotypes) and its association with clinical manifestations and biomarkers related to the disease activity were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>B2-CIC prevalence in APS patients was 39.3%. B2-CIC-positive patients with thrombotic APS presented a higher incidence of thrombocytopenia (OR: 2.32, p=0.007), heart valve thickening and dysfunction (OR: 9.06, p=0.015) and triple aPL positivity (OR: 1.83, p=0.027), as well as lower levels of C3, C4 and platelets (p-values: &amp;lt;0.001, &amp;lt;0.001 and 0.001) compared to B2-CIC-negative patients. B2-CIC of IgM isotype were significantly more prevalent in gestational than thrombotic APS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with thrombotic events and positive for B2-CIC had lower platelet count and complement levels than those who were negative, suggesting a greater degree of platelet activation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.957201","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:57:01Z","timestamp":1662969421000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Circulating immune-complexes of IgG\/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Laura","family":"Naranjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljudmila","family":"Stojanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Djokovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ma\u015bli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garcinu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Kostyra-Grabczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Regola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milomir","family":"Milanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovica","family":"Saponjski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pleguezuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082265","article-title":"Primary, secondary, and catastrophic antiphospholipid syndrome: What\u2019s in a name","volume":"34","author":"Harris","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0482-z","article-title":"Catastrophic APS in the context of other thrombotic microangiopathies","volume":"17","author":"Rodriguez-Pinto","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0320-8","article-title":"Valvular heart disease in antiphospholipid syndrome","volume":"15","author":"Zuily","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2017.06.004","article-title":"Central nervous system manifestations of antiphospholipid syndrome","volume":"43","author":"Graf","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"B6","article-title":"Livedo reticularis: An enigma","volume":"17","author":"Sangle","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395052","article-title":"Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): Thrombocytopenia and skin manifestations","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8972","DOI":"10.3390\/ijms21238972","article-title":"The weight of IgA anti-beta2glycoprotein I in the antiphospholipid syndrome pathogenesis: Closing the gap of seronegative antiphospholipid syndrome","volume":"21","author":"Cabrera-Marante","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00376","article-title":"Reliability of lupus anticoagulant and anti-phosphatidylserine\/prothrombin autoantibodies in antiphospholipid syndrome: A multicenter study","volume":"10","author":"Sciascia","year":"2019","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178889","article-title":"Incidence of thromboembolic events in asymptomatic carriers of IgA anti ss2 glycoprotein-I antibodies","volume":"12","author":"Tortosa","year":"2017","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: Understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04327.x","article-title":"beta(2)-glycoprotein I: Evolution, structure and function","volume":"9","author":"de Groot","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221088576","article-title":"The pathophysiology of the antiphospholipid syndrome: A perspective from the blood coagulation system","volume":"28","author":"Arreola-Diaz","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.9.900","article-title":"Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome","volume":"97","author":"George","year":"1998","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1023\/B:JOCI.0000018058.28764.ce","article-title":"Antiphospholipid syndrome infectious origin","volume":"24","author":"Blank","year":"2004","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.9.5164","article-title":"Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides","volume":"96","author":"Blank","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4054","article-title":"Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation-mechanisms analyzed using hydrogen\/deuterium exchange","volume":"30","author":"Tang","year":"2021","journal-title":"Protein Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206483","article-title":"Antibodies to domain I of beta-2-glycoprotein I and IgA antiphospholipid antibodies in patients with \u2018seronegative\u2019 antiphospholipid syndrome","volume":"74","author":"Cousins","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200614","article-title":"Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called \u2018seronegative APS\u2019)","volume":"71","author":"Rodriguez-Garcia","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5551\/jat.34488","article-title":"Circulating immune complexes of IgA bound to beta 2 glycoprotein are strongly associated with the occurrence of acute thrombotic events","volume":"23","author":"Martinez-Flores","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2015.04.002","article-title":"Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology","volume":"422","author":"Martinez-Flores","year":"2015","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025992","article-title":"Beta2-glycoprotein I\/IgA immune complexes: A marker to predict thrombosis after renal transplantation in patients with antiphospholipid antibodies","volume":"135","author":"Serrano","year":"2017","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02891","article-title":"Immune complexes of beta-2-Glycoprotein I and IgA antiphospholipid antibodies identify patients with elevated risk of thrombosis and early mortality after heart transplantation","volume":"10","author":"Serrano","year":"2019","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02644","article-title":"Presence of immune complexes of IgG\/IgM bound to B2-glycoprotein I is associated with non-criteria clinical manifestations in patients with antiphospholipid syndrome","volume":"9","author":"Perez","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.micron.2017.04.005","article-title":"Visualization of macro-immune complexes in the antiphospholipid syndrome by multi-modal microscopy imaging","volume":"100","author":"Taatjes","year":"2017","journal-title":"Micron"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1191\/096120399678847470","article-title":"Beta2 glycoprotein I containing immune-complexes in lupus patients: Association with thrombocytopenia and lipoprotein (a) levels","volume":"8","author":"George","year":"1999","journal-title":"Lupus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312440347","article-title":"Circulating beta2 glycoprotein I-IgG anti-beta2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome","volume":"21","author":"Banzato","year":"2012","journal-title":"Lupus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"European League against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. subcommittee on lupus Anticoagulant\/Antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(90)90276-2","article-title":"Detection of circulating immune complexes with polyethylene glycol precipitation F(ab\u2019)2 anti-C3 ELISA","volume":"135","author":"Xu","year":"1990","journal-title":"J Immunol Methods"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"B37","volume-title":"Instructor\u2019s manual to accompany fundamental statistics in psychology and education","author":"Guilford","year":"1973"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14633","article-title":"The (non-)sense of detecting anti-cardiolipin and anti-beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/jcm11030675","article-title":"Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: A comprehensive review","volume":"11","author":"Alijotas-Reig","year":"2022","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS","volume":"39","author":"McDonnell","year":"2020","journal-title":"Blood Rev"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1007\/1-4020-8056-5_24","article-title":"Activation and inhibition of complement by immunoglobulins","volume-title":"The complement system: Novel roles in health and disease","author":"Basta","year":"2004"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0645-x","article-title":"Complement activation, a threat to pregnancy","volume":"40","author":"Girardi","year":"2018","journal-title":"Semin Immunopathol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.04.008","article-title":"Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome","volume":"75","author":"Bertolaccini","year":"2016","journal-title":"J Autoimmun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102914","article-title":"Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages","volume":"188","author":"Bosmann","year":"2012","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01522.x","article-title":"Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma","volume":"102","author":"Norda","year":"2012","journal-title":"Vox Sang"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0022-1759(00)00139-3","article-title":"A quantitative approach to the determination of antigen in immune complexes","volume":"237","author":"Nezlin","year":"2000","journal-title":"J Immunol Methods"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/BF02207930","article-title":"Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome","volume":"14","author":"Pengo","year":"1995","journal-title":"Clin Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1191\/0961203305lu2145rr","article-title":"Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis","volume":"14","author":"Atsumi","year":"2005","journal-title":"Lupus"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283507","article-title":"Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: A 6-year follow-up study","volume":"116","author":"Comellas-Kirkerup","year":"2010","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.6.1760","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study","volume":"98","author":"Diz-Kucukkaya","year":"2001","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02310.x","article-title":"Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein ibalpha and apolipoprotein e receptor 2\u2019","volume":"5","author":"Pennings","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.03.005","article-title":"The hematologic manifestations of the antiphospholipid syndrome","volume":"22","author":"Uthman","year":"2008","journal-title":"Blood Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0673-5","article-title":"Anti-beta2GPI\/beta2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: A pathway to targeted therapies","volume":"13","author":"Zhang","year":"2019","journal-title":"Front Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.21968","article-title":"Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein ib-IX-V","volume":"54","author":"Shi","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-576983","article-title":"Platelets as pivot in the antiphospholipid syndrome","volume":"124","author":"de Groot","year":"2014","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1994.1032","article-title":"Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice","volume":"7","author":"Blank","year":"1994","journal-title":"J Autoimmun"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.149.3.1063","article-title":"Anticardiolipin antibodies in NZW x BXSB F1 mice. a model of antiphospholipid syndrome","volume":"149","author":"Hashimoto","year":"1992","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378646","article-title":"The significance of autoantibodies against beta2-glycoprotein I","volume":"120","author":"de Groot","year":"2012","journal-title":"Blood"},{"key":"B67","volume-title":"Cellular and molecular immunology","author":"Abbas","year":"2018"},{"key":"B68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000330664","article-title":"Immune complex-mediated complement activation in a patient with IgG4-related tubulointerstitial nephritis","volume":"1","author":"Nagamachi","year":"2011","journal-title":"Case Rep Nephrol Urol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-005-0007-y","article-title":"Antibodies against C1q in patients with systemic lupus erythematosus","volume":"27","author":"Trendelenburg","year":"2005","journal-title":"Springer Semin Immunopathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2011.04.024","article-title":"Complement activation by (auto-) antibodies","volume":"48","author":"Daha","year":"2011","journal-title":"Mol Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.020","article-title":"Complement and thrombosis in the antiphospholipid syndrome","volume":"15","author":"Oku","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu391oa","article-title":"Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment","volume":"12","author":"Lockshin","year":"2003","journal-title":"Committee Consensus Rep Lupus"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: Retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000240","article-title":"Recognition and management of antiphospholipid syndrome","volume":"28","author":"Gerosa","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.02.003","article-title":"The treatment of anti-phospholipid syndrome: A comprehensive clinical approach","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1136\/gut.32.8.876","article-title":"Fc receptor function and circulating immune complexes in gluten sensitive enteropathy\u2013possible significance of serum IgA","volume":"32","author":"Lavo","year":"1991","journal-title":"Gut"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.624025","article-title":"Complement receptors and their role in leukocyte recruitment and phagocytosis","volume":"9","author":"Vandendriessche","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1988.tb02423.x","article-title":"Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes","volume":"28","author":"Kavai","year":"1988","journal-title":"Scand J Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00945","article-title":"Functional roles of the IgM fc receptor in the immune system","volume":"10","author":"Kubagawa","year":"2019","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00099","article-title":"Emerging functions of natural IgM and its fc receptor FCMR in immune homeostasis","volume":"7","author":"Wang","year":"2016","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.957201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T19:21:56Z","timestamp":1676748116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.957201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2022.957201"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.957201","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"957201"}}